Publication Information

{'id': 'https://openalex.org/W2418692205', 'doi': None, 'title': 'Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.', 'display_name': 'Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.', 'publication_year': 2010, 'publication_date': '2010-06-01', 'ids': {'openalex': 'https://openalex.org/W2418692205', 'mag': '2418692205', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/20587343'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/20587343', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5045902068', 'display_name': 'Yu‐Yun Shao', 'orcid': 'https://orcid.org/0000-0001-7334-1912'}, 'institutions': [{'id': 'https://openalex.org/I75357094', 'display_name': 'National Yunlin University of Science and Technology', 'ror': 'https://ror.org/04qkq2m54', 'country_code': 'TW', 'type': 'education', 'lineage': ['https://openalex.org/I75357094']}, {'id': 'https://openalex.org/I4210131804', 'display_name': 'National Taiwan University Hospital', 'ror': 'https://ror.org/03nteze27', 'country_code': 'TW', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210131804']}], 'countries': ['TW'], 'is_corresponding': False, 'raw_author_name': 'Yu-Yun Shao', 'raw_affiliation_strings': ['Department of Oncology, National Taiwan University Hospital-Yunlin Branch, 360 Xingzhong, Yunlin, Taipei, Taiwan.'], 'affiliations': [{'raw_affiliation_string': 'Department of Oncology, National Taiwan University Hospital-Yunlin Branch, 360 Xingzhong, Yunlin, Taipei, Taiwan.', 'institution_ids': ['https://openalex.org/I75357094', 'https://openalex.org/I4210131804']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5043008228', 'display_name': 'Chia‐Chi Lin', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Chia-Chi Lin', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5055074037', 'display_name': 'James Chih‐Hsin Yang', 'orcid': 'https://orcid.org/0000-0002-5586-5138'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Chih-Hsin Yang', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 2, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 1.477, 'has_fulltext': False, 'cited_by_count': 12, 'citation_normalized_percentile': {'value': 0.755054, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 85, 'max': 86}, 'biblio': {'volume': '9', 'issue': '49', 'first_page': '538', 'last_page': '45'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9989, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9989, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11067', 'display_name': 'Colorectal Cancer Treatments and Studies', 'score': 0.9561, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10755', 'display_name': 'HER2/EGFR in Cancer Research', 'score': 0.9524, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/erlotinib-hydrochloride', 'display_name': 'Erlotinib Hydrochloride', 'score': 0.51633847}], 'concepts': [{'id': 'https://openalex.org/C2778087573', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib', 'level': 4, 'score': 0.98799324}, {'id': 'https://openalex.org/C2780580887', 'wikidata': 'https://www.wikidata.org/wiki/Q417824', 'display_name': 'Gefitinib', 'level': 4, 'score': 0.9854413}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.71074533}, {'id': 'https://openalex.org/C2779438470', 'wikidata': 'https://www.wikidata.org/wiki/Q424401', 'display_name': 'Epidermal growth factor receptor', 'level': 3, 'score': 0.6508696}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.64977115}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.6221881}, {'id': 'https://openalex.org/C535046627', 'wikidata': 'https://www.wikidata.org/wiki/Q30612', 'display_name': 'Clinical trial', 'level': 2, 'score': 0.5734027}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.5299854}, {'id': 'https://openalex.org/C2909325608', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib Hydrochloride', 'level': 5, 'score': 0.51633847}, {'id': 'https://openalex.org/C2778820342', 'wikidata': 'https://www.wikidata.org/wiki/Q906415', 'display_name': 'Tyrosine-kinase inhibitor', 'level': 3, 'score': 0.43293837}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.33635768}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.27061254}], 'mesh': [{'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D002289', 'descriptor_name': 'Carcinoma, Non-Small-Cell Lung', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D008175', 'descriptor_name': 'Lung Neoplasms', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D011799', 'descriptor_name': 'Quinazolines', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D002289', 'descriptor_name': 'Carcinoma, Non-Small-Cell Lung', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D002986', 'descriptor_name': 'Clinical Trials as Topic', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000069347', 'descriptor_name': 'Erlotinib Hydrochloride', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000077156', 'descriptor_name': 'Gefitinib', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008175', 'descriptor_name': 'Lung Neoplasms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011799', 'descriptor_name': 'Quinazolines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/20587343', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being', 'score': 0.81}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W2166084034', 'https://openalex.org/W2043696829'], 'abstract_inverted_index': {'Tyrosine': [0], 'kinase': [1], 'inhibitors': [2], 'of': [3, 17, 34, 101, 112, 132], 'the': [4, 14, 32, 39, 71, 98, 102, 117, 130], 'epidermal': [5], 'growth': [6], 'factor': [7], 'receptor,': [8], 'gefitinib': [9, 35, 51, 77, 113], 'and': [10, 82, 89, 106], 'erlotinib,': [11], 'have': [12, 30], 'changed': [13], 'treatment': [15], 'paradigm': [16], 'advanced': [18, 58], 'non-small': [19], 'cell': [20], 'lung': [21], 'cancer': [22], '(NSCLC).': [23], 'Many': [24], 'phase': [25], 'II': [26], 'or': [27, 36, 42, 52, 65, 78], 'III': [28], 'studies': [29, 103], 'proven': [31], 'efficacy': [33, 90, 131], 'erlotinib': [37, 53, 79, 115], 'as': [38], 'first-line,': [40], 'second-line,': [41], 'third-line': [43], 'treatment.': [44], 'However,': [45], 'it': [46], 'is': [47, 124, 138], 'not': [48], 'clear': [49], 'whether': [50], 'has': [54], 'different': [55, 62, 67], 'activities': [56], 'in': [57, 80, 92, 136], 'NSCLC': [59, 81, 137], 'patients': [60], 'with': [61], 'clinicopathological': [63], 'features': [64], 'at': [66, 127], 'stages.': [68], 'We': [69], 'review': [70], 'published': [72], 'clinical': [73, 119], 'trials': [74, 94], 'that': [75, 95, 129], 'used': [76], 'compare': [83], 'their': [84], 'efficacy.': [85], 'The': [86, 108], 'selection': [87], 'criteria': [88], 'measurement': [91], 'these': [93, 133], 'might': [96], 'affect': [97], 'final': [99], 'results': [100], 'are': [104, 121], 'listed': [105], 'discussed.': [107], 'adequate-powered,': [109], 'direct': [110], 'comparisons': [111], 'against': [114], 'under': [116], 'same': [118], 'scenarios': [120], 'lacking.': [122], 'There': [123], 'no': [125], 'evidence': [126], 'present': [128], 'two': [134], 'agents': [135], 'different.': [139]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2418692205', 'counts_by_year': [{'year': 2017, 'cited_by_count': 2}, {'year': 2015, 'cited_by_count': 2}, {'year': 2014, 'cited_by_count': 2}, {'year': 2013, 'cited_by_count': 1}, {'year': 2012, 'cited_by_count': 4}], 'updated_date': '2024-12-07T16:46:08.021830', 'created_date': '2016-06-24'}